Tune Therapeutics
Tune Therapeutics raises $175M Series B at $900M valuation
Quick Facts
Tune Therapeutics: Series B Funding Round
Tune Therapeutics has successfully raised $175M in Series B funding, reaching a valuation of $900M.
Company Overview
Epigenetic gene regulation therapies
Funding Details
The Series B round was led by Hevolution, with participation from NEA, Regeneron Ventures.
Company Information
- Headquarters: Durham, NC
- Founded: 2021
- Employees: 100+
- Category: Biotech
Investment
Tune Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Hevolution: Verified investor in Series B
- NEA: Verified investor in Series B
- Regeneron Ventures: Verified investor in Series B
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
